Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Nature Communications
|
March 29, 2013
Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells
Euan S Polson, John L Lewis, Hamza Celik, et al.
FEBS Letters
|
August 31, 2019
Notch signalling is a potential resistance mechanism of progenitor cells within patient-derived prostate cultures following ROS-inducing treatments
John R Packer, Adam M Hirst, Alastair P Droop, et al.
European Urology
|
September 20, 2014
MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets
Jayant K Rane, Mauro Scaravilli, Antti Ylipää, et al.
European Urology Open Science
|
August 2, 2021
Overexpression of Placental Growth Factor in Stromal Cells from Benign Prostatic Hyperplasia: Another Piece in the Puzzle?
Conor M Devlin, Fiona M Frame, Leanne K Archer, et al.
Oncotarget
|
September 17, 2017
Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
Dominika E Butler, Christopher Marlein, Hannah F Walker, et al.
Plos One
|
May 16, 2013
Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells
Engin Ulukaya, Fiona M Frame, Buse Cevatemre, et al.
Molecular Cancer
|
August 2, 2011
Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer
Davide Pellacani, Richard J Packer, Fiona M Frame, et al.
FEBS Open Bio
|
April 26, 2022
ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate
Leanne K Archer, Fiona M Frame, Hannah F Walker, et al.
European Urology Oncology
|
June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
Beth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Nature Communications
|
March 29, 2013
Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells
Euan S Polson, John L Lewis, Hamza Celik, et al.
FEBS Letters
|
August 31, 2019
Notch signalling is a potential resistance mechanism of progenitor cells within patient-derived prostate cultures following ROS-inducing treatments
John R Packer, Adam M Hirst, Alastair P Droop, et al.
European Urology
|
September 20, 2014
MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets
Jayant K Rane, Mauro Scaravilli, Antti Ylipää, et al.
European Urology Open Science
|
August 2, 2021
Overexpression of Placental Growth Factor in Stromal Cells from Benign Prostatic Hyperplasia: Another Piece in the Puzzle?
Conor M Devlin, Fiona M Frame, Leanne K Archer, et al.
Oncotarget
|
September 17, 2017
Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
Dominika E Butler, Christopher Marlein, Hannah F Walker, et al.
Plos One
|
May 16, 2013
Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells
Engin Ulukaya, Fiona M Frame, Buse Cevatemre, et al.
Molecular Cancer
|
August 2, 2011
Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer
Davide Pellacani, Richard J Packer, Fiona M Frame, et al.
FEBS Open Bio
|
April 26, 2022
ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate
Leanne K Archer, Fiona M Frame, Hannah F Walker, et al.
European Urology Oncology
|
June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
Beth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Page
of 2